Last reviewed · How we verify
Discontinue Clopidogrel
Clopidogrel is a prodrug that is metabolized to its active form by CYP450 enzymes, primarily CYP2C19, which irreversibly inhibits platelet aggregation by blocking the P2Y12 receptor on platelets.
Clopidogrel is a prodrug that is metabolized to its active form by CYP450 enzymes, primarily CYP2C19, which irreversibly inhibits platelet aggregation by blocking the P2Y12 receptor on platelets. Used for Prevention of atherothrombotic events in patients with recent myocardial infarction, recent stroke, or established peripheral arterial disease.
At a glance
| Generic name | Discontinue Clopidogrel |
|---|---|
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Drug class | antiplatelet |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Clopidogrel acts as an antiplatelet agent by selectively inhibiting the P2Y12 receptor, which is involved in the ADP-mediated activation of platelets. This inhibition prevents the amplification of the platelet activation process and reduces the formation of thrombi.
Approved indications
- Prevention of atherothrombotic events in patients with recent myocardial infarction, recent stroke, or established peripheral arterial disease
Common side effects
- bleeding
- neutropenia
- thrombocytopenia
Key clinical trials
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
- OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina (NA)
- Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM) (NA)
- Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |